Electrocore Llc (ECOR)
NASDAQ:ECOR
Want to see ECOR full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.44Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated a strong quarter of execution: record revenue, significant YoY growth, higher gross margins (87%), and meaningful improvement in adjusted EBITDA loss, all while reaffirming full-year guidance. Management also highlighted multiple catalysts (VA and DoD expansion, TruVega international launch, Quell OTC relaunch, R&D/clinical progress including PTSD work) and added experienced commercial leadership. Key risks discussed include a decrease in cash balances, Q1 seasonal cash burn and near-term capital timing, ongoing GAAP losses driven by nonrecurring charges, concentrated product penetration in the VA (only ~2.5%), and historically variable TACSTIM revenue. On balance, the positives around accelerating revenue, margin expansion, improving adjusted EBITDA, product and channel momentum, and clear operational priorities outweigh the near-term financial and execution risks presented on the call.Company Guidance
Record Quarterly Revenue and Strong Top-Line Growth
Q1 2026 revenue of $9.6M, the highest quarter on record, up 43% year-over-year. Company reaffirmed full-year 2026 revenue guidance of ~30% growth (roughly $9M–$10M incremental vs. $32M in 2025).
Improving Profitability Metrics and Operating Leverage
Gross profit of $8.4M with gross margin expanding to 87% (a 200 basis point improvement YoY). Adjusted EBITDA loss narrowed 24% to a $2.3M loss from $3.1M in the prior year, demonstrating operating leverage.
Strong VA Prescription Performance
VA prescription device revenue grew 48% YoY to $7.9M. Prescription gammaCore sales grew 26% within that mix. Approximately 15,000 VA patients have received gammaCore, representing an early penetration (~2.5%) of the addressable VA headache market.
Consumer Wellness Momentum (TruVega)
Consumer wellness channel revenue reached $1.6M, up 44% YoY, with TruVega contributing $1.5M (up 38% YoY). Return on advertising spend (ROAS) improved to ~2.37, a 14% improvement quarter-over-quarter, with return rates steady at 12%–15%.
Quell Acquisition Progress and Product Rollouts
Quell sales surpassed their first $1M quarter; cumulative Quell revenue since acquisition is ~$2.5M–$2.7M (including ~$2.5M of Quell fibromyalgia sales in the VA). Company plans a deliberate relaunch of Quell Relief (OTC) later in the year.
Leadership, Commercial Channel Expansion and R&D Catalysts
New COO Mike Fox added deep federal/commercial experience and is focused on increasing VA depth and expanding DoD/federal channels. TACSTIM engaged in multiple DoD research programs. R&D progress includes Acacia PTSD study enrollment and recent publications supporting nVNS; PTSD has Breakthrough Device designation. TruVega launched in the U.K. (Jan 2026).
ECOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ECOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $6.66 | $6.27 | -5.86% |
Mar 19, 2026 | $6.55 | $6.25 | -4.65% |
Nov 05, 2025 | $4.74 | $5.84 | +23.21% |
Aug 06, 2025 | $6.93 | $4.91 | -29.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Electrocore Llc (ECOR) report earnings?
Electrocore Llc (ECOR) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Electrocore Llc (ECOR) earnings time?
Electrocore Llc (ECOR) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ECOR EPS forecast?
ECOR EPS forecast for the fiscal quarter 2026 (Q2) is -0.38.